ANVS

Annovis BioF

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$1.80

-3.2% vs current

Most likely

Base case

50%

Probability

Target price

$0.90

-51.6% vs current

B-

Bear case

30%

Probability

Target price

$0.45

-75.8% vs current

AI sentiment snapshot

Latest data as of 2025-11-30

AI commentary

Market tone is cautious to negative given low price and high dilution probability; commentary centers on financing risk and binary clinical outcomes [#10Qp12], [#PR-2025-07-15]. Recent trading volume and press suggest limited investor conviction, with occasional speculative spikes tied to trial rumors [#news-week].

RankAlpha Sentiment AI - 2025-11-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-01-31catalystFinancing / dilutionHigh impact

Need for additional capital could lead to dilution and downward pressure if raised at low prices; likelihood elevated for early‑stage biotechs [#10Qp12].

2026-03-31eventRegulatory interactions / FDA feedbackHigh impact

Positive or negative regulatory feedback on development pathways could materially re-rate valuation given small market cap and binary outcomes [#10Qp12].

2026-06-30eventClinical data readouts / trial updatesHigh impact

Potential Phase 2/extension study updates or safety/tolerability disclosures for lead programs may move the stock [#10Qp12], [#PR-2025-07-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-30 • Updated nightlySource: Internal modelMethodology